Regeneron Pharmaceuticals (REGN) Stock Price, Quote, News & History

Comments

Regeneron Pharmaceuticals Inc (REGN) Stock Price, Quote, News & History

REGNNASDAQ

Trade with Public

$748.75

-5.18-0.69%

Last update: Apr 16, 1:38 PM

Earnings: Q1 2026 Earnings in 13 days from now on Wed Apr 29th, before the market open

OverviewNews Earnings Options Dividends Analyst Ratings Insider Trades Short Interest Government Trades Stock Report

Key Statistics

Open

$749.56

Close

-

Volume / Avg.

151.77K / 716.57K

Day Range

$746.40 - $756.00

52 Wk Range

476.49 - 821.11

Market Cap

$78.69B

P/E Ratio

18.18

Dividend Yield

0.50%

Exchange

NASDAQ

RSI

47

Short Interest

2.56%

Days to Cover

4.22

Recent Regeneron Pharmaceuticals Inc News

Ocular's Axpaxli Cuts Risk Of Worsening In Late-Stage AMD Study

Ocular Therapeutix shares up on positive data for wet AMD treatment. Company focusing on retinal diseases and on track for FDA submission.

Vandana Singh

Telix Pharma Gains As Regeneron Tie-Up Targets Solid Tumor Programs

Telix collaborates with Regeneron, targeting radiopharmaceutical development, with milestones up to $2.1 billion and royalties.

Vandana Singh

From Lungs To Nasal Polyps: Sanofi Finds Success With 2-in-1 Inflammation Blocker

Sanofi reports positive Phase 2 data for lunsekimig in asthma and nasal polyps, while atopic dermatitis study misses main goal.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

4.98B

Investing Cash Flow (TTM)

-629.10M

Financing Cash Flow (TTM)

-3.72B

Free Cash Flow (TTM)

3.77B

Capital Expenditure (TTM)

-1.21B

Net Change in Cash (TTM)

634.40M

Analyst Trends and Forecast

2

3

Dec 25

3

Jan

5

2

Feb

3

Mar

1

Apr

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

3.4

Hold

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$73.81B

PE Ratio (TTM)

18.18

PE Ratio (FWD)

17.51

PEG Ratio (TTM)

1.61

PS Ratio (TTM)

5.71

PB Ratio (TTM)

2.55

Earnings Yield % (TTM)

5.50%

Earnings Yield % (FWD)

5.71%

EV / EBITDA (TTM)

12.69

Price / EBITDA (TTM)

14.07

Price / Free Cash Flow (TTM)

21.75

Book Value / Share

$295.66

Company Debt

Total Debt

$1.99B

LT Debt

$1.99B

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$3.12B

Debt to Equity

0.09

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

$749.56

Close

-

Volume / Avg.

151.77K / 716.57K

Day Range

$746.40 - $756.00

52 Wk Range

476.49 - 821.11

Market Cap

$78.69B

P/E Ratio

18.18

Dividend Yield

0.50%

Exchange

NASDAQ

RSI

47

Short Interest

2.56%

Days to Cover

4.22

About

Sector

Health Care

Industry

Biotechnology

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet ag...

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS better than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS better than industry

FAQ

Q

How do I buy Regeneron Pharmaceuticals (REGN) stock?

A

You can purchase shares of Regeneron Pharmaceuticals (NASDAQ:REGN) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Regeneron Pharmaceuticals (REGN) competitors?

A

Other companies in Regeneron Pharmaceuticals’s space includes: BeOne Medicines Ltd (NASDAQ:ONC), Neurocrine Biosciences Inc (NASDAQ:NBIX), Ionis Pharmaceuticals Inc (NASDAQ:IONS), Roivant Sciences Ltd (NASDAQ:ROIV) and Amgen Inc (NASDAQ:AMGN).

Q

What is the forecast, or price target, for Regeneron Pharmaceuticals (REGN) stock?

A

Regeneron Pharmaceuticals has a consensus price target of $850.60.

Q

What is the current price for Regeneron Pharmaceuticals (REGN)?

A

The stock price for Regeneron Pharmaceuticals (NASDAQ: REGN) is $748.745 last updated April 16, 2026 at 1:38 PM EDT.

Q

Does Regeneron Pharmaceuticals (REGN) pay a dividend?

A

There are no upcoming dividends for Regeneron Pharmaceuticals.

Q

When is Regeneron Pharmaceuticals (NASDAQ:REGN) reporting earnings?

A

Regeneron Pharmaceuticals does not have any upcoming earnings scheduled.

Q

Is Regeneron Pharmaceuticals (REGN) going to split?

A

There is no upcoming split for Regeneron Pharmaceuticals.

Q

What sector and industry does Regeneron Pharmaceuticals (REGN) operate in?

A

Regeneron Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

People Also Watch

Neurocrine Biosciences Inc

NASDAQ:NBIX

$129.20

-1.70%

Ionis Pharmaceuticals Inc

United Therapeutics Corp

Key Statistics

Open

$749.56

Close

-

Volume / Avg.

151.77K / 716.57K

Day Range

$746.40 - $756.00

52 Wk Range

476.49 - 821.11

Market Cap

$78.69B

P/E Ratio

18.18

Dividend Yield

0.50%

Exchange

NASDAQ

RSI

47

Short Interest

2.56%

Days to Cover

4.22

Recent Regeneron Pharmaceuticals Inc News

Ocular's Axpaxli Cuts Risk Of Worsening In Late-Stage AMD Study

Ocular Therapeutix shares up on positive data for wet AMD treatment. Company focusing on retinal diseases and on track for FDA submission.

Vandana Singh

Telix Pharma Gains As Regeneron Tie-Up Targets Solid Tumor Programs

Telix collaborates with Regeneron, targeting radiopharmaceutical development, with milestones up to $2.1 billion and royalties.

Vandana Singh

From Lungs To Nasal Polyps: Sanofi Finds Success With 2-in-1 Inflammation Blocker

Sanofi reports positive Phase 2 data for lunsekimig in asthma and nasal polyps, while atopic dermatitis study misses main goal.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

4.98B

Investing Cash Flow (TTM)

-629.10M

Financing Cash Flow (TTM)

-3.72B

Free Cash Flow (TTM)

3.77B

Capital Expenditure (TTM)

-1.21B

Net Change in Cash (TTM)

634.40M

Analyst Trends and Forecast

2

3

Dec 25

3

Jan

5

2

Feb

3

Mar

1

Apr

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

3.4

Hold

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$73.81B

PE Ratio (TTM)

18.18

PE Ratio (FWD)

17.51

PEG Ratio (TTM)

1.61

PS Ratio (TTM)

5.71

PB Ratio (TTM)

2.55

Earnings Yield % (TTM)

5.50%

Earnings Yield % (FWD)

5.71%

EV / EBITDA (TTM)

12.69

Price / EBITDA (TTM)

14.07

Price / Free Cash Flow (TTM)

21.75

Book Value / Share

$295.66

Company Debt

Total Debt

$1.99B

LT Debt

$1.99B

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$3.12B

Debt to Equity

0.09

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

$749.56

Close

-

Volume / Avg.

151.77K / 716.57K

Day Range

$746.40 - $756.00

52 Wk Range

476.49 - 821.11

Market Cap

$78.69B

P/E Ratio

18.18

Dividend Yield

0.50%

Exchange

NASDAQ

RSI

47

Short Interest

2.56%

Days to Cover

4.22

About

Sector

Health Care

Industry

Biotechnology

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet ag...

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS better than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS better than industry